Keyword: PARP inhibitors

5. Niraparib

Niraparib wouldn't be the first PARP-inhibiting drug on the market, but Tesaro is hoping that its entry will launch with a bigger target, thanks to study data showing it delivered benefits not only to women with the BRCA gene mutation, but those without.